{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:27:57Z","timestamp":1779272877868,"version":"3.51.4"},"reference-count":167,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.jneuroim.2009.04.015","type":"journal-article","created":{"date-parts":[[2009,5,14]],"date-time":"2009-05-14T05:11:21Z","timestamp":1242277881000},"page":"132-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recombinant interferon-beta therapy and neuromuscular disorders"],"prefix":"10.1016","volume":"212","author":[{"given":"Joerg-Patrick","family":"St\u00fcbgen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2009.04.015_bib1","first-page":"349","article-title":"Peripheral sensory and motor abnormalities in patients with multiple sclerosis","volume":"43","author":"Anlar","year":"2003","journal-title":"Electromyogr. Clin. Neurophysiol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1445-5994.1972.tb03071.x","article-title":"Multiple sclerosis and autoimmune diseases","volume":"2","author":"Baker","year":"1972","journal-title":"Aust. N.Z. J. Med."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib3","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.1093\/emboj\/17.23.6888","article-title":"Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling","volume":"17","author":"Balachandran","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1128\/JVI.74.3.1513-1523.2000","article-title":"Alpha\/beta interferons potentiate virus-induced apoptosis through activation of FADD\/capsase-8 death signaling pathway","volume":"74","author":"Balachandran","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","article-title":"Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study","volume":"5","author":"Barcellos","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.immunol.17.1.189","article-title":"Natural killer cells in antiviral-defense: function and regulation by innate cytokines","volume":"17","author":"Biron","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib7","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1212\/WNL.49.6.1747-a","article-title":"Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment","volume":"49","author":"Blake","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/BOR.0b013e328010c547","article-title":"Syndromes and complications of interferon therapy","volume":"19","author":"Borg","year":"2007","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/intimm\/14.4.411","article-title":"IFN\u03b1\/\u03b2 enhances BCR-dependent B cell responses","volume":"14","author":"Braun","year":"2002","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/123.6.1102","article-title":"Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey","volume":"123","author":"Broadley","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ana.410410517","article-title":"Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon \u03b2-1b","volume":"41","author":"Calabresi","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00415-006-0136-9","article-title":"Mononeuropathy following subcutaneous interferon-\u03b2 injection","volume":"253","author":"Capasso","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","article-title":"Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies","volume":"54","author":"Choi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF00919601","article-title":"Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"242","author":"Choudhary","year":"1995","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1517\/14712598.7.4.535","article-title":"Interferon-beta 1a for the treatment of multiple sclerosis","volume":"7","author":"Clerico","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib16","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s00415-005-0876-y","article-title":"Treatment of refractory chronic demyelinating polyneuropathy with interferon \u03b21b","volume":"252","author":"Cocco","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1212\/WNL.49.3.857","article-title":"Frequency and significance of antinuclear antibodies in multiple sclerosis","volume":"49","author":"Collard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0404.1997.tb00300.x","article-title":"No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing\u2013remitting multiple sclerosis","volume":"96","author":"Colosimo","year":"1997","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jnen\/59.2.164","article-title":"Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies","volume":"59","author":"Confalonieri","year":"2000","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/08916930310001602137","article-title":"Potential mechanisms of interferon-alpha induced autoimmunity","volume":"36","author":"Conrad","year":"2003","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1468-1331.2006.01422.x","article-title":"Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis","volume":"13","author":"Coppola","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.1997.269-ce1161.x","article-title":"Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans","volume":"107","author":"Corssmit","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/107999000750053690","article-title":"Biologic responses to IFN-alpha administration in humans","volume":"20","author":"Corssmit","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib24","first-page":"19","article-title":"Myasthenia gravis and multiple sclerosis: a review of the ocular manifestations","volume":"31","author":"Costello","year":"2006","journal-title":"Insight"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0035-3787(04)71160-1","article-title":"Involvement of the peripheral nervous system in multiple sclerosis","volume":"160","author":"Couratier","year":"2004","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1073\/pnas.94.2.634","article-title":"Interferon-\u03b1\/\u03b2 inhibition of interleukin-12 and interferon-\u03b3 production in vitro and endogenously during viral infection","volume":"94","author":"Cousens","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00063030-200014010-00001","article-title":"A role for interferon-beta in Guillain-Barr\u00e9 syndrome?","volume":"14","author":"Cr\u00e9ange","year":"2000","journal-title":"BioDrugs"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/jnnp.68.3.395","article-title":"Focal neuropathy associated with cutaneous necrosis at the site of interferon-\u03b2 injection for multiple sclerosis","volume":"68","author":"Cr\u00e9ange","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(05)60466-7","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with interferon-\u03b2","volume":"352","author":"Cr\u00e9ange","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1212\/WNL.38.3.371","article-title":"Autoimmunity in multiple sclerosis","volume":"38","author":"De Keyser","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-5728(97)00170-7","article-title":"Interferon beta normalizes suppressor cell function in dysimmune neuropathies","volume":"82","author":"De Luca","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jnnp.2003.028233","article-title":"Development of myasthenia gravis in two patients with multiple sclerosis following interferon \u03b2 treatment","volume":"75","author":"Dionisiotis","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib33","first-page":"135","article-title":"Multiple sclerosis associated with peripheral demyelinating neuropathy","volume":"15","author":"Di Trapani","year":"1996","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib34","doi-asserted-by":"crossref","first-page":"21606","DOI":"10.1074\/jbc.270.37.21606","article-title":"Cloning and expression of the long form of the beta subunit of the interferon alpha beta receptor that is required for signaling","volume":"270","author":"Domanski","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/jnnp.72.5.676","article-title":"Interferon \u03b2-1a treatment of corticosteroid sensitive polymyositis","volume":"72","author":"Dressel","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-510X(98)00299-8","article-title":"Autoimmune events during interferon beta-1b treatment for multiple sclerosis","volume":"162","author":"Durelli","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib37","series-title":"The Cytokine Handbook","first-page":"1233","article-title":"Interferon \u03b1: biology, pharmacology and therapy for chronic viral hepatitis","author":"Dusheiko","year":"2003"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1191\/1352458504ms1087oa","article-title":"A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic","volume":"10","author":"Edwards","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/01.wnl.0000171858.82527.4c","article-title":"Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis","volume":"65","author":"Ekstein","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0190-9622(97)70170-1","article-title":"Cutaneous reactions to recombinant human interferon beta-1b; the clinical and histological spectrum","volume":"37","author":"Elgart","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0115426505020004369","article-title":"The cancer cachexia syndrome: a review of metabolic and clinical manifestations","volume":"20","author":"Esper","year":"2005","journal-title":"Nutr. Clin. Pract."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib42","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","author":"European Study Group on interferon beta-1b in secondary progressive MS","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0167-5699(00)01710-2","article-title":"Type I interferons and T helper development","volume":"21","author":"Farrar","year":"2000","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib44","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.4049\/jimmunol.163.8.4473","article-title":"Upregulation of NK cytotoxic activity via IL-15 induction by various viruses: a comparative study","volume":"163","author":"Fawaz","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib45","first-page":"584","article-title":"Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2\u2032,5\u2032 oligoadenylate synthetase induction","volume":"58","author":"Feldman","year":"1988","journal-title":"Lab. Invest."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-510X(81)90007-1","article-title":"Conduction velocity and conduction block in experimental ischaemic nerve injury","volume":"52","author":"Fowler","year":"1981","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jnen\/60.9.847","article-title":"Cathepsins are upregulated by IFN-gamma\/STAT1 in human muscle culture: a possible active factor in dermatomyositis","volume":"60","author":"Gallardo","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib48","first-page":"574","article-title":"Therapeutic mechanisms of interferon-beta and intravenous immunoglobulin for experimental peripheral neuropathy","volume":"45","author":"Gao","year":"2007","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneuroim.2007.04.008","article-title":"Clinical and MRI correlates of autoreactve antibodies in multiple sclerosis patients","volume":"187","author":"Garg","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib50","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/BOR.0b013e328313644c","article-title":"Inclusion body myositis: new insights into pathogenesis","volume":"20","author":"Garlepp","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib51","first-page":"2352","article-title":"Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial","volume":"54","author":"Goodkin","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib52","series-title":"Abstract [P07.101], 60th Annual Meeting, American Academy of Neurology, Chicago, April 12\u201319","article-title":"Efficacy of interferon beta-1a in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)","author":"Gorson","year":"2008"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0003-9993(94)90135-X","article-title":"Electrodiagnostic abnormalities in patients with multiple sclerosis","volume":"75","author":"Grana","year":"1994","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib54","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.WNL.0000291619.17160.b8","article-title":"Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications","volume":"69","author":"Greenberg","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11910-009-0013-x","article-title":"Inclusion body myositis: review of recent literature","volume":"9","author":"Greenberg","year":"2009","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib56","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib57","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.53.1.57","article-title":"Randomized trial of interferon beta-1a in chronic inflammatory polyradiculoneuropathy","volume":"53","author":"Hadden","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-510X(99)00082-9","article-title":"Exacerbation of myasthenia gravis in a patient after interferon-\u03b2 treatment for chronic active hepatitis C","volume":"165","author":"Harada","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410300110","article-title":"Serum inter-leukin-2 concentrations in Guillain-Barr\u00e9 syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis","volume":"30","author":"Hartung","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib61","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1212\/WNL.8.7.503","article-title":"Peripheral neuropathy in multiple sclerosis","volume":"8","author":"Hasson","year":"1958","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib62","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1054\/jocn.2000.0693","article-title":"The occurrence of autoimmune diseases in patients with multiple sclerosis","volume":"7","author":"Henderson","year":"2000","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib63","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b in effective in relapsing\u2013remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN\u03b2 Multiple Sclerosis Study Group","volume":"43","author":"IFN\u03b2 Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib64","first-page":"22","article-title":"Polymyositis after interferon beta treatment of chronic hepatitis type C","volume":"36","author":"Iguchi","year":"1996","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/jir.1997.17.263","article-title":"Interferons suppress mitochondrial gene transcription by depleting mitochondrial transcription factor A (mt TFA)","volume":"17","author":"Inagaki","year":"1997","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib66","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E","article-title":"Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy","volume":"43","author":"Ioannou","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1006\/jaut.1996.0078","article-title":"Global inhibition of IL-2 and IFN-gamma secreting T cells precedes recovery from acute experimental autoimmune encephalomyelitis","volume":"9","author":"Jensen","year":"1996","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib69","doi-asserted-by":"crossref","first-page":"11813","DOI":"10.1073\/pnas.94.22.11813","article-title":"The crystal structure of human interferon \u03b2 at 2.2-\u00c5 resolution","volume":"94","author":"Karpusas","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2249.1999.01020.x","article-title":"Interferon-\u03b1 (IFN-\u03b1) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway","volume":"118","author":"Kaser","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","article-title":"Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system","volume":"30","author":"Kieseier","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib72","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","article-title":"Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy","volume":"20","author":"Kirkwood","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0404.1998.tb05960.x","article-title":"No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis","volume":"97","author":"Kivisakk","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib74","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(03)00390-5","article-title":"Autoimmune aspects of cytokine and anticytokine therapies","volume":"115","author":"Krause","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib75","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity","volume":"131","author":"Krumholz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib76","first-page":"489","article-title":"8-year follow-up of the European Study of Interferon beta-1-b (EUSPMS) in secondary progressive MS","volume":"62","author":"Kuhle","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib77","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1212\/WNL.53.6.1364","article-title":"Interferon-beta 1a in chronic inflammatory demyelinating polyneuropathy","volume":"53","author":"Kuntzer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","article-title":"Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial","volume":"60","author":"Leary","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib79","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type I interferons potentially enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo","volume":"14","author":"LeBon","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1152\/ajpcell.00120.2007","article-title":"IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium","volume":"294","author":"Lechner","year":"2008","journal-title":"Am. J. Physiol., Cell Physiol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib81","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.wco.0000175937.31569.15","article-title":"Multifocal motor neuropathy","volume":"18","author":"L\u00e9ger","year":"2005","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib82","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ana.410400606","article-title":"Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis","volume":"40","author":"Leppert","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<307::AID-MUS1>3.0.CO;2-U","article-title":"Type I interferons and chronic inflammatory demyelinating polyneuropathy: treatment or cause?","volume":"23","author":"Lisak","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib84","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/jnnp.72.2.274","article-title":"Rhabdomyolysis during interferon-\u03b2 1a treatment","volume":"72","author":"L\u00fcnemannn","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib85","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1002\/j.1460-2075.1995.tb00192.x","article-title":"Mutant U5A cells are complemented by an interferon-alpha beta subunit generated by alternative processing of a new member of a cytokine receptor gene cluster","volume":"14","author":"Lutfalla","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib86","series-title":"Basic and Clinical Principles","first-page":"469","article-title":"The immune response","author":"Mak","year":"2006"},{"issue":"Supplement 4","key":"10.1016\/j.jneuroim.2009.04.015_bib87","first-page":"S8","article-title":"Interferon-beta: mechanism of action and dosing issues","volume":"68","author":"Markowitz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib88","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.189.3.521","article-title":"Type I interferons keep activated T cells alive","volume":"189","author":"Marrack","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib89","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.66.2.197","article-title":"Chronic motor neuropathies: response to interferon-\u03b21a after failure of conventional therapies","volume":"66","author":"Martina","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2169\/internalmedicine.44.68","article-title":"Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferon beta-1b therapy in a patient with childhood-onset multiple sclerosis","volume":"4","author":"Matsuse","year":"2005","journal-title":"Intern. Med."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib91","first-page":"805","article-title":"Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia","volume":"22","author":"Melstrom","year":"2007","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib92","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.1996.tb00004.x","article-title":"Multiple sclerosis and chronic inflammatory diseases. A case-control study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib93","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","article-title":"Approaches for identifying and defining environmentally associated rheumatic disorders","volume":"43","author":"Miller","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib94","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/WNL.56.5.666","article-title":"Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy","volume":"56","author":"Misawa","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib95","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.clinph.2008.04.010","article-title":"Peripheral nerve demyelination in multiple sclerosis","volume":"119","author":"Misawa","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib96","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1056\/NEJM198004103021519","article-title":"False-positive immunoassay for acetylcholine-receptor antibody in amyotrophic lateral sclerosis","volume":"302","author":"Mittag","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"Supplement1","key":"10.1016\/j.jneuroim.2009.04.015_bib97","first-page":"62","article-title":"Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis","volume":"10","author":"Montalban","year":"2004","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib98","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.6606850","article-title":"Endogenous regulation of macrophage proliferative expansion by CSF-induced interferon","volume":"223","author":"Moore","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib99","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.21103","article-title":"Activation of endoplasmic reticulum stress response in autoimmune myositis: a potential role in muscle fiber damage and dysfunction","volume":"52","author":"Nagaraju","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/76940","article-title":"Interferon alpha\/beta-mediated inhibition and promotion of interferon gamma: STAT resolves a paradox","volume":"1","author":"Nguyen","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib101","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/1352458508088936","article-title":"Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark","volume":"14","author":"Nielsen","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib102","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/mus.20296","article-title":"Multifocal motor neuropathy: current concepts and controversies","volume":"31","author":"Nobile-Orazio","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib103","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ana.410270219","article-title":"Interferon augments suppressor cell function in multiple sclerosis","volume":"27","author":"Noronha","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib104","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-5728(93)90244-S","article-title":"Interferon \u03b2 decreases T cell activation and interferon \u03b3 production in multiple sclerosis","volume":"46","author":"Noronha","year":"1993","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","article-title":"The human interferon alpha\/beta receptor: characterization and molecular cloning","volume":"77","author":"Novick","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib106","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/35636","article-title":"Requirement for IRF-1 in the microenvironment supporting development of natural killer cells","volume":"391","author":"Ogasawara","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib107","first-page":"236","article-title":"Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-\u03b2","volume":"108","author":"Ozenci","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410110207","article-title":"Selective fiber vulnerability in acute ischemic neuropathy","volume":"11","author":"Parry","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib109","first-page":"179","article-title":"Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers","volume":"14","author":"Pedrol","year":"1995","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib110","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/01.WNL.0000064163.94122.EB","article-title":"Contrasting effects of IFN beta and IVIG in children with central and peripheral demyelination","volume":"60","author":"Pirko","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib111","first-page":"257","article-title":"Subclinical lesions of peripheral nervous system in multiple sclerosis patients","volume":"38","author":"Pogorzelski","year":"2004","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib112","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410020107","article-title":"Peripheral nerve abnormality in multiple sclerosis","volume":"2","author":"Pollock","year":"1977","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib113","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.WNL.0000154522.86947.86","article-title":"Interferon beta-1b treatment does not induce autoantibodies","volume":"64","author":"Polman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0165-5728(95)00070-I","article-title":"Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients","volume":"61","author":"Porrini","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib115","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","author":"PRISMS Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib116","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","article-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Pritchard","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib117","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0969-2126(96)00152-9","article-title":"Zinc mediated dimmer of human interferon-\u03b12b revealed by X-ray crystallography","volume":"4","author":"Radhakrishnan","year":"1996","journal-title":"Structure"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib118","first-page":"273","article-title":"Long term follow up in chronic inflammatory demyelinating polyneuropathy (CIDP) under interferon beta-1a (IFN-[beta]1a) and intravenous immunoglobulin (IVIg)","volume":"70","author":"Radziwill","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib119","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/pgmj.2007.066209","article-title":"Multifocal motor neuropathy: review of a treatable immune mediated disorder","volume":"84","author":"Rajabally","year":"2008","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S1474-4422(07)70132-1","article-title":"Autoimmune disease in families with multiple sclerosis: a population-based study","volume":"6","author":"Ramagopalan","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib121","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","article-title":"Campylobacter jejuni infection and Guillain-Barr\u00e9 syndrome","volume":"333","author":"Rees","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib122","doi-asserted-by":"crossref","first-page":"16351","DOI":"10.1016\/S0021-9258(19)84711-7","article-title":"Tumor necrosis factor acts synergistically with autocrine interferon-\u03b2 and increases interferon-\u03b2 mRNA levels in human fibroblasts","volume":"264","author":"Reis","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib123","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3181\/00379727-131-34066","article-title":"Resistance to virus challenge in mice infected with protozoa or bacteria","volume":"131","author":"Remington","year":"1969","journal-title":"J. Biol. Exp. Biol. Med."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib124","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00415-005-0748-5","article-title":"Interferon beta in relapsing\u2013remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre","volume":"252","author":"Rio","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/jir.1989.9.649","article-title":"Constitutive expression of a 2\u2032,5\u2032-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression","volume":"9","author":"Rysiecki","year":"1989","journal-title":"J. Interferon Res."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib126","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1212\/01.WNL.0000151856.10387.E2","article-title":"Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study","volume":"64","author":"Saida","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib127","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0404.1995.tb06996.x","article-title":"Peripheral neuropathy in multiple sclerosis: a clinical and electrophysiologic study","volume":"91","author":"Sarova-Pinhas","year":"1995","journal-title":"Acta Neurol. Scad."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib128","first-page":"888","article-title":"Evaluation of 4 cases with clinical characteristics of myasthenia gravis and multiple sclerosis","volume":"15","author":"Satoyoshi","year":"1975","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib129","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(05)60356-X","article-title":"Interferon beta for Guillain-Barr\u00e9 syndrome","volume":"351","author":"Sawaya","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000050798","article-title":"Successful treatment of Guillain-Barr\u00e9 syndrome with combined administration of interferon-\u03b2-1a and intravenous immunoglobulin","volume":"46","author":"Schaller","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0404.1990.tb00928.x","article-title":"Multiple sclerosis and other immunologic diseases","volume":"81","author":"Seyfert","year":"1990","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib132","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1002\/j.1460-2075.1990.tb07879.x","article-title":"Interferon selectively inhibits the expression of mitochondrial genes: a novel pathway for interferon-mediated responses","volume":"9","author":"Shan","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib133","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/CND.0b013e31816f18e3","article-title":"Chronic demyelinating polyradiculoneuropathy associated with multiple sclerosis","volume":"9","author":"Sharma","year":"2008","journal-title":"J. Clin. Neuromusc. Dis."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib134","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clineuro.2006.10.003","article-title":"Interferon causes no myasthenia in a seropositive patient with multiple sclerosis","volume":"109","author":"Shimizu","year":"2007","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib135","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type I interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib136","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","article-title":"Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling","volume":"144","author":"Somani","year":"2008","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib137","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-510X(89)90005-1","article-title":"Myasthenia gravis associated with multiple sclerosis: epidemiological survey and immunological findings","volume":"89","author":"Somer","year":"1989","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib138","series-title":"The Cytokine Handbook","first-page":"549","article-title":"Type I interferons","author":"Soos","year":"2003"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib139","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/135245859900500209","article-title":"Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies","volume":"5","author":"Spadaro","year":"1999","journal-title":"Mult. Scler."},{"issue":"Supplement 2","key":"10.1016\/j.jneuroim.2009.04.015_bib140","first-page":"S57","article-title":"Serum auto-antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b","volume":"6","author":"Speciale","year":"2000","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib141","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.56.11.1496","article-title":"Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results","volume":"56","author":"SPECTRIMS Study Group","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib142","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib143","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ana.410400607","article-title":"Interferon beta-1b decreases migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9","volume":"40","author":"St\u00fcve","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib144","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.onc.1201712","article-title":"Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line","volume":"16","author":"Subramaniam","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2443.1998.00164.x","article-title":"Type I interferons are essential mediators of apoptotic cell death in virally infected cells","volume":"3","author":"Tanaka","year":"1998","journal-title":"Genes Cells"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib146","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of \u03b2IFN1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"The Muscle Study Group","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib147","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose \u03b2INF-1a in patients with inclusion body myositis","volume":"63","author":"The Muscle Study Group","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib148","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib149","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/gast.1997.v112.pm9041265","article-title":"New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine","volume":"112","author":"Tilg","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib150","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1126\/science.272.5270.1947","article-title":"Induction of bystander T cell proliferation by viruses and type I interferon in vivo","volume":"272","author":"Tough","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib151","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/0002-9378(95)90402-6","article-title":"Interferons: biochemistry and mechanisms of action","volume":"172","author":"Tyring","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib152","first-page":"71","article-title":"The receptor of the type I interferon family","volume":"316","author":"Uz\u00e9","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"Supplement","key":"10.1016\/j.jneuroim.2009.04.015_bib153","first-page":"S23","article-title":"Interferon beta-1a as an investigational treatment for CIDP","volume":"60","author":"Vallat","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib154","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1212\/WNL.54.7.1518","article-title":"Treatment of multifocal motor neuropathy with interferon-\u03b21A","volume":"54","author":"Van den Berg-Vos","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib155","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/107999002753536220","article-title":"Autoantibodies in multiple sclerosis patients before and during IFN\u03b2-1b treatment: are they correlated with the occurrence of autoimmune diseases?","volume":"22","author":"Verdun","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib156","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1590\/S0004-282X2004000500031","article-title":"Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: a case report","volume":"62","author":"Villa","year":"2004","journal-title":"Arq. Neuro-Psiquiatr."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib157","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/08916939608995361","article-title":"Oral administration of type I interferon modulates the course of experimental allergic neuritis","volume":"24","author":"Vriesendorp","year":"1996","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib158","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type 1 interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib159","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2340\/00015555577146148","article-title":"Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature","volume":"77","author":"Weinberg","year":"1997","journal-title":"Acta Derm.-Venerol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib160","first-page":"251","article-title":"The interferon genes","volume":"33","author":"Weissman","year":"1986","journal-title":"Proc. Nucl. Acid Res."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib161","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1212\/01.WNL.0000133411.10574.BA","article-title":"Interferon \u03b2-responsive inclusion body myositis in a hepatitis C virus carrier","volume":"63","author":"Yakushiji","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib162","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1089\/107999000750053799","article-title":"Cytochrome c release, mitochondrial membrane depolarization, capase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells","volume":"20","author":"Yanase","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib163","first-page":"61","article-title":"Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha","volume":"112","author":"You","year":"1999","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib164","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0165-5728(00)00397-0","article-title":"Regulation of chemokine receptor CCR 5 and production of RANTES and MIP-1 alpha by interferon-beta","volume":"112","author":"Zang","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.04.015_bib165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.41.3.457-a","article-title":"Peripheral nervous system involvement in multiple sclerosis","volume":"41","author":"Zee","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib166","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1074-7613(00)80564-6","article-title":"Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15","volume":"8","author":"Zhang","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2009.04.015_bib167","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1097-4547(19990415)56:2<123::AID-JNR2>3.0.CO;2-G","article-title":"IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue","volume":"56","author":"Zou","year":"1999","journal-title":"J. Neurosci. Res."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572809001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572809001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:12:55Z","timestamp":1759047175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572809001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":167,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0165572809001490"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2009.04.015","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant interferon-beta therapy and neuromuscular disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2009.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}